{"name":"CEL-SCI Corporation","slug":"cel-sci-corporation","ticker":"","exchange":"","domain":"","description":"CEL-SCI Corporation is a biotechnology company focused on developing treatments for cancer and infectious diseases. The company's lead product, Multikine, was in late-stage clinical trials but has since been discontinued. CEL-SCI continues to explore other potential applications of its technology.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"LI","genericName":"LI","slug":"li","indication":"Metastatic renal cell carcinoma","status":"marketed"}]}],"pipeline":[{"name":"LI","genericName":"LI","slug":"li","phase":"marketed","mechanism":"LI is an immunotherapeutic agent designed to enhance immune response against cancer cells.","indications":["Metastatic renal cell carcinoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNelRlX1ZBZE1uajZBcjIzY3lySmktancxUGFCWlZJMFFkc1VuS1dXUmRwZlZVRGg0UlJGMm54WXAyOVVWR1RUM0oyOW9RNXEzbW9VUF9GLTJ4SXp0aTZFX29yYkUyZEF5V1JPZkR4YmJTdUFjYXpUVkJvM3JKWi1weElmQkE0YjE1LUJ4MURkNk9rY0ViUVd6ZkZGOWYxUQ?oc=5","date":"2026-04-01","type":"pipeline","source":"openPR.com","summary":"Leading Companies Reinforcing Their Presence in the Liposomal Drug Delivery Devices Market - openPR.com","headline":"Leading Companies Reinforcing Their Presence in the Liposomal Drug Delivery Devices Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNZFhobEYyVlpka3FaNFRGSUNBOGJUUnVmS245NW9PYXN1aWlKY01jUVdqZUN3UW1PMDVEbktQcDZORVktYktUcVpwRnhzb1dzLURvRlpUSjQ0RnF0bmIzZ0doMUNTYndTVkVaSE45ZFlMeTZKblYxdnBtaUc1VTVPbVkxSkI1c29LRzFVcGEtVjhHNmJOWkJZaXc3QnpnVGZKX29VSmppZEVtZF9wMkZrdDNINy0?oc=5","date":"2026-03-09","type":"pipeline","source":"Benzinga","summary":"12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga","headline":"12 Health Care Stocks Moving In Monday's Pre-Market Session","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxNN1phZG1mTW9wUTVvekRrQi1pMGs2WWh3eWFHaURrQ1hZUFN6SXN2VjB2Qy1ZRnpPSVhCOC1vNFJTTlNzNlBxdUFRUzRHSmF3SERlcE9vX3g3RE4zeG1yMFJpN2tNNG9KVldybFl5eHVUX3ZRTm5pSWxBLVRzVHZUaExBLWI1akRTaGQ4S3RaRHdiOXg4UFpGY3lvMnFBM3BGSVU3WURfLWR2NlUxU1FTNWE2TnJ0SW0yUkNnaURlN3RaanQteTlPRVpOTXJZWXZoYTFYM2xSc0M0X25wc2dadGFKQno?oc=5","date":"2025-10-15","type":"pipeline","source":"Stocktwits","summary":"Retail Buzz Builds Around Cel-Sci Stock Ahead Of Saudi Ruling On Cancer Drug Multikine - Stocktwits","headline":"Retail Buzz Builds Around Cel-Sci Stock Ahead Of Saudi Ruling On Cancer Drug Multikine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNUHZpQVliTHpleWhJYW5IM19RT0dTQVpzQ0c4SjJqdnRDZ2J1QVN5YVh5Nk5HRHhMRmRUekxUdG5XVm5Ma25VRk9tcjlPSEV3NkZ0TjQzaE4tVFF1R2VEN0lQM3FxRmZrQ1hMQTdBc3NlYmJOOWNSYzJkRDdCdHJXLVI1anJFSEZ4dENFOGx4U1Y0Z09TUzZreElfbldwd0oxZ1N5T0NuZEUwZE5IV0dTMHU3YjNRZw?oc=5","date":"2025-08-28","type":"pipeline","source":"BioBuzz","summary":"Cel-Sci’s $10M Raise Fuels Dual-Track US and Saudi Arabian Strategy for Multikine - BioBuzz","headline":"Cel-Sci’s $10M Raise Fuels Dual-Track US and Saudi Arabian Strategy for Multikine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE1VVkZhNTFTM1VzdnFnYnd4eHBSMFlSZ0F3cGkwcWJGOU1fWVVaS3lPR3VzanlSOHZaY2xIS0dGQ3R3Y3V2WkQtTGNTWkQ4ZjBHQkFzZU81SHMwN2M1Rk9lRlY5WXlFX2pzbUNUeW1aV3Y2SFV6MTlQWHcySXl4MDg?oc=5","date":"2025-08-14","type":"earnings","source":"Yahoo Finance","summary":"CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results - Yahoo Finance","headline":"CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-13","type":"pipeline","source":"Business Wire","summary":"CEL-SCI’s Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which ","headline":"CEL-SCI’s Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows f","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNbGo2SU5qQkhpdi04R0g1SmkyNEl4cU4tanVKdG5zYUNTNEJuNjhPaTdtYWpTc3ppdW9IX0NUQnd1UklsMWRvaUVzS1MwUDJwdjlHUU8zNVBxRzRiNkJHV0dhWFcxLUFDVGVEc3lrTzBhNmh4bXhhelk2ajdmRnNBREZEWEV2S1VDbE9uNFBGZFpZUWx0ZC1lSXV1ckRUelhvcUZ3UVFRR0NVX0RqVk1JRjlsS2dhc1JpdWdhc2kyTQ?oc=5","date":"2025-08-13","type":"pipeline","source":"Investing.com","summary":"Saudi pharma company files breakthrough designation for Multikine - Investing.com","headline":"Saudi pharma company files breakthrough designation for Multikine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxNcC1UWnFIQzJ2YktFMzVuZGlkd2hULXFzdmJzMUVUT0d1ZHNDLXBPSlU0Q25TdExPQzVZbFpQME9OZWlFVWFwdFg5RzBmZ2tUOEhLNW8xVDRjcHFnTnZ0QnVfYnljVnhJZm5KRkxyMHdLeDJoajRUU3NSMTdIWUJIVzNHNnJrZmVKOG5EZmR6dUdxY0NwcFRtYjZ6eWhmNzBjTGNXbnI2NHZTMURaUDB0em4tT3lweUUtYVJiTUpkLTBHX2hOd1BHSEJSWlFQUFBBeExEdEVtNTJtejYwWDdwOEJJaFNrTHFQcFE?oc=5","date":"2025-07-14","type":"pipeline","source":"BioPharma APAC","summary":"CEL-SCI Aligns with Saudi Pharma Leader to Fast-Track Multikine Access Under Breakthrough Medicine Designation - BioPharma APAC","headline":"CEL-SCI Aligns with Saudi Pharma Leader to Fast-Track Multikine Access Under Breakthrough Medicine Designation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNZDllc0NKcUR2N2tNM3FLR2IxeThwa2JjQWloVDhwUlJJQ09FQjV2TlNOeGtqdWYzOVZZMnNtdml0bm1faUctdjVpTlhtNUpPNUIyWUVsRFpsMUF3TVdUamw1aU50Y21QdnBxU2c3UklWTUMwbmttdGFrT0NpaFprNzdCZTFDVnl0Y3RRRlZzZFRtMlg2QWxRdFNwYkFiWTR2d3RB?oc=5","date":"2025-07-14","type":"deal","source":"World Pharmaceutical Frontiers","summary":"CEL-SCI collaboration to advance Multikine access in Saudi Arabia - World Pharmaceutical Frontiers","headline":"CEL-SCI collaboration to advance Multikine access in Saudi Arabia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgJBVV95cUxNbEcyd3BsUlR2OHIzQnJIcjJFb2ZQX1c4X2JGVkZWQ3RZbTYzSFNycjIybUFIWnVjWWdtOTlwSVhVamttYzRWaDNhUWdOa1NMbW9rVmJRT25hVG52SllMb3RsaHJwbnRwRThyT041a0V5cjVITGxWQy0xbTd5VU1kTXE0ZlZOYjNoQkV5YkdzMllsTVFEZzJENDRhcmpyOXRfU3JqRFdWMzQ4UGFLNXRkX3pPLVhQMFFOVzR2Qi1MM19RM19XMm1tLWFSSGxVcGhtXzN1SkMtN3VHQkZmQVFXd2VkSHVKQ1l4eWhxQkxVMnRhbGpmeWlUSkU4VENwVi1vNHE5Qlc1YVUzWlFfYWN1Z0k1TWswQQ?oc=5","date":"2025-07-11","type":"deal","source":"Business Wire","summary":"CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer - Business Wire","headline":"CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head &","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxPMHhVOUJLdlNuMkcxSEotNndNLVhtSWRLdDZYaC1odUstLWd3SEdrMVAzV0JaLVA0QWJONkVxZlg4NWlCNUR4ZkJLRGFPVF9kd0s3TlVYYnlQOWluWklWUDUzRHJ1Nmo2cEEzQ1VGYVVvaElsX0NEbmF6aVB1WDZscTU4RlhvckprSmh5a21GQXBramxYYmtOYlJTSU1QSGtEWUhObTB5ME0xT0FaTEZvdFRrd2xtWjl5ZGc1MjZ4ajkzSG92RVNnT1B1N2NPWjlrUExRdlBMUFU?oc=5","date":"2025-07-11","type":"deal","source":"Stocktwits","summary":"CEL-SCI Stock Soars On Imminent Partnership With Saudi Arabian Pharma Company For Cancer Drug: Retail’s Thrilled - Stocktwits","headline":"CEL-SCI Stock Soars On Imminent Partnership With Saudi Arabian Pharma Company For Cancer Drug: Retail’s Thrilled","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxNU1pBem5uYlp6YzNhU3VNRmJBRXo1QkxKazRRTWJhN3Jta3VVWW1NVUt3MTRpOHVXUy05NnpjUG1xU0lnV2FXelBJU2VVVjY1U1FhaG13eTd2MDZOUlJIQl9WZzM3T1ZnZVVuaDhkcHVJRElIVVdDeklkTmxTSDF6eVVKZ3JoV1Bib1JBSlRaeThMVUsyek9NeVZzS1ZPZ1o1eVg4Q1BXdXVMYWVobzZrNWROTlpBY1ByQVluOHNhVXROcGFrclgwZ0dGcDM?oc=5","date":"2025-07-11","type":"deal","source":"Investing.com","summary":"CEL-SCI partners with Saudi pharmaceutical firm to bring Multikine to market - Investing.com","headline":"CEL-SCI partners with Saudi pharmaceutical firm to bring Multikine to market","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}